Markets:

Overview

News

Currencies

International

Treasuries

Prime Medicine, Inc. - Common Stock (NQ:PRME)

3.420 -0.170 (-4.74%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Prime Medicine, Inc. - Common Stock

< Previous 1 2 3 Next >

Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday ↗

September 30, 2024

Via Benzinga

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline ↗

September 30, 2024

Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones. The company...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 30, 2024

Via Benzinga

2 Growth Stocks That Could Make You Richer ↗

August 28, 2024

Discover two cutting-edge growth stocks that could revolutionize medicine and space exploration.

Via The Motley Fool

Recap: Prime Medicine Q4 Earnings ↗

March 01, 2024

Via Benzinga

PRME Stock Earnings: Prime Medicine Misses EPS for Q2 2024 ↗

August 08, 2024

PRME stock results show that Prime Medicine missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names ↗

May 29, 2024

Between FDA approvals and product pipelines, it takes diligence to keep up with which biotech stocks to buy.

Via InvestorPlace

Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio ↗

May 25, 2024

Alphabet may have strong insight into both company's industries.

Via The Motley Fool

Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 ↗

May 17, 2024

Discover three biotech stocks handpicked by Cathie Wood, offering groundbreaking therapies and substantial growth potential.

Via InvestorPlace

Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 ↗

May 17, 2024

With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead.

Via InvestorPlace

PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024 ↗

May 10, 2024

PRME stock results show that Prime Medicine beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket ↗

May 02, 2024

Via Benzinga

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 29, 2024

Via Benzinga

Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday ↗

April 29, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

April 29, 2024

Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday!

Via InvestorPlace

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 26, 2024

Via Benzinga

2 Magnificent Growth Stocks With Room to Run ↗

March 27, 2024

These deeply undervalued growth stocks could be big winners for patient shareholders.

Via The Motley Fool

Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging ↗

March 14, 2024

Explore short-squeeze stocks for potential surges, spotlighting investor strategies and trends that could benefit your portfolio.

Via InvestorPlace

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? ↗

March 01, 2024

On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks.

Via InvestorPlace

Morgan Stanley Reports Q4 Results, Joins Boeing, Alcoa And Other Big Stocks Moving Lower On Tuesday ↗

January 16, 2024

U.S. stocks traded lower, with the Dow Jones index falling more than 250 points on Tuesday.

Via Benzinga

Topics Stocks

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

December 22, 2023

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

Via Benzinga

Better Growth Stock: Archer Aviation or Prime Medicine? ↗

December 19, 2023

Which of these innovation-themed growth stocks is the better buy?

Via The Motley Fool

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years ↗

November 30, 2023

This gene-editing company could sport a best-in-class platform.

Via The Motley Fool

Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 06, 2023

Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge...

Via Benzinga

Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

November 06, 2023

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

DISH Network, Goodyear And 3 Stocks To Watch Heading Into Monday ↗

November 06, 2023

With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

7 Biotech Stocks to Get In Now Before Investors Catch On ↗

October 23, 2023

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

Via InvestorPlace

Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst ↗

October 09, 2023

BMO Capital Markets has initiated coverage on Prime Medicine Inc (NASDAQ: PRME), a preclinical-stage company focused on developing therapies based on prime editing.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023 ↗

October 09, 2023

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Prime Medicine, Inc. - Common Stock (NQ:PRME)

Headline News about Prime Medicine, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today